Clinical Trial Listing

Page Text Size:

Government approved Clinical Trials for Treatment of NF2

In a search for treatments for NF2 (Neurofibromatosis Type 2), Clinical Studies, are underway and are at different stages. The list for these studies can all be found in the table below. More on the individual studies can be found in the referring link for each trial listed. Treatment aka Intervention type, for NF2 consists of 2 categories:

Method:

Observation and Tests - These are the NIH (National Institutes of Health) Studies.
Drug - Bevacizumab (Avastin), Lapatinib, RAD001 (Everolimus), PTC299, Sunitinib

Device: ABI (Auditory Brain Stem Implant)

VS (Vestibular Schwannoma) aka AN (Acoustic Neuroma) are an issue for people with NF2, even if these tumors can be caused for reasons other then NF2. But this means people with NF2 would also qualify for Clinical Trials for people with VS.

NF2 Clinical Trials

Status	As Of (YMD)	Intervention	Study Name
Recruiting	2011-03-09	Biological: Bevacizumab	Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Completed	2005-06-23	Device: Multichannel ABI	Phase II Study of the Multichannel ABI for Deafness Following Surgery for NF2
Completed	2006-01-31	Device: Penetrating ABI	An Implant for Hearing Loss Due to Removal of NF2 Tumors
Active, Not Recruiting	2011-09-08	Drug: Bevacizumab	Bevacizumab for Symptomatic VS in NF2
Active, Recruiting	2012-01-27	Drug: Lapatinib	Concentration and Activity of Lapatinib in VS's
Active, Not Recruiting	2011-04-05	Drug: Lapatinib	Lapatinib Study for Children and Adults With NF2 and NF2-Related Tumors
Active, Not Recruiting	2011-06-07	Drug: PTC299	PTC299 for Treatment of NF2
Recruiting	2012-01-16	Drug: RAD001	Efficacy and Safety Study of RAD001 in the Growth of the VS's in NF2 Patients (AFINF2) - Paris
Active, Not Recruiting	2012-01-13	Drug: RAD001, Everolimus	Study of RAD001 for Treatment of NF2-related VS
Not Recruiting Yet	2012-01-23	Drug: RAD001, Everolimus	Phase II Study of Everolimus (RAD001) in Children and Adults With NF2
Recruiting	2011-11-21	Drug: Sunitinib	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Unknown	2010-07-28	Drug: Sunitinib Malate	Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma, Intracranial Hemangiopericytoma, or Intracranial Hemangioblastoma
Completed	2005-09-27	Method: Observation & Tests	NF2 Natural History Consortium
Recruiting	2011-12-22	Method: Observation & Tests	Natural History Study of Patients With NF2
Completed	2008-03-03	Method: Observation & Tests	Analysis of NF2 Mutations in Radiation-Related Neural Tumors

NF2 NYC Support Group, New York
Email: Lori Davila at lori@nf2nycsupport.org
Copyright © 2008 - 2012

DISCLAIMER: www.nf2nycsupport.org is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. While we hope the information found on the www.nf2nycsupport.org site is helpful in offering suggestions in topics to discuss with your doctor, information found here should not be considered actual medical advice. Medical advice should always be sought by consultation with a medical professional.